Healthcare · Profile from Healthcare Research Companion
Siemens Healthineers AG
The medical technology arm of Siemens, born in the X-ray workshops of Erlangen within months of Röntgen's discovery and listed separately in Frankfurt in 2018. Siemens Healthineers is the largest of the "big three" imaging makers by revenue. It sells CT, MRI, X-ray, molecular imaging and ultrasound; one of the world's largest laboratory diagnostics businesses; and, since its ~$16.4bn purchase of Varian (agreed 2020, closed 2021), radiation therapy for cancer. It led the industry into photon-counting CT. Its weak spot has been laboratory diagnostics, bought for over $13bn in 2006–07 and restructured repeatedly since; in 2026 it is being prepared for a carve-out. In November 2025 its parent announced it would spin off 30% of the shares directly to Siemens shareholders, ending Siemens' control after more than a century.
At a glance
- Founded
- Medical business roots in Erlangen (Reiniger, Gebbert & Schall, 1886) and Siemens & Halske X-ray tubes (1896); merged as Siemens-Reiniger-Werke (1932); Siemens Medical Solutions / Siemens Healthcare; renamed Siemens Healthineers in 2016; listed 2018
- Founders
- Erwin Moritz Reiniger (RGS); Werner von Siemens's company Siemens & Halske
- Headquarters
- Erlangen, Germany (registered address in Forchheim in 2026 releases; a new corporate headquarters is being built in Erlangen)
- Ownership / structure
- Listed on Frankfurt Stock Exchange (SHL, IPO 16 March 2018; DAX member since the index expanded to 40 on 20 September 2021). Siemens AG holds ~67% (2025); plans to transfer 30% directly to Siemens shareholders under the German Transformation Act, leaving it ~37%; vote at Siemens' February 2027 AGM (announced April 2026)
- Leadership (2026)
- Bernd Montag, CEO (head of Siemens Healthcare from 2015); Jochen Schmitz, CFO
- Segments
- Through FY2025: Imaging, Diagnostics, Varian, Advanced Therapies. From FY2026 (1 October 2025): Imaging (prevention and detection), Precision Therapy (Varian plus Advanced Therapies), Diagnostics (run on a standalone basis; carve-out being prepared)
- Payer and customer
- Hospitals, imaging centres, laboratories, cancer centres; national health systems and insurers pay for the procedures and tests
- Scale
- FY2025 (ended 30 September 2025) revenue ~€23.4bn (+5.9% comparable); adjusted EBIT margin 16.5%; free cash flow ~€2.7bn; Diagnostics ~€4.35bn (−2%); tariff cost ~€200m in FY2025, ~€400m expected FY2026 (reported). FY2026 guidance cut twice (5–6% → 4.5–5.0% in May → 3.5–4.0% comparable growth in July 2026) as Diagnostics shrank, while adjusted EPS guidance was raised to €2.35–2.45 by IEEPA tariff refunds. ~74,300 employees (30 June 2026)
- Capital / market cap
- IPO raised ~€4.2bn (2018, all to Siemens); two share placements (~€2.73bn September 2020, ~€2.34bn March 2021) plus Siemens loans financed Varian; market cap roughly €50–60bn in 2025 (approximate)
- Signature moves (incl. failures)
- Erlangen X-ray origins (1896); diagnostics buying spree (2006–07) and later impairments; Frankfurt IPO (2018); Corindus vascular robotics bet and exit (2019–23); Varian (2021); NAEOTOM Alpha photon-counting CT (2021); diagnostics restructuring and carve-out (2023–26); Siemens deconsolidation plan (2025–27)
8 strategic moves analysed
Each one gets a full strategy file in the companion: context, the decision, the financing, what happened, and the lesson.
1896
Erlangen X Ray Origins
Founding (entry into medical imaging)
2006
Diagnostics Buying Spree
Acquisitions (three deals)
2018
Frankfurt IPO
IPO (partial listing of a conglomerate subsidiary)
2019
Corindus Robotics Bet and Exit
Acquisition, later exit
2020
Varian Acquisition
Acquisition
2021
NAEOTOM Alpha Photon Counting CT
Launch (new imaging technology)
2023
Diagnostics Restructuring and Carve Out
Restructuring, then divestiture preparation
2025
Siemens Deconsolidation Plan
Spin-off (planned, by parent)